Review of the first chapter of the second Trump administration, including key domains relevant to the industry, including insurance and PBM reform, drug pricing and negotiations, and international trade agreements. Covering the latest on the Inflation Reduction Act, the Biosecure Act and reforms driven by new leadership at the Department of HHS and CMS. Where are the opportunities for industry, key risks and ongoing uncertainties to monitor?